{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Time from response to relapse. Response would have been assessed using European Group for Blood and Marrow Transplantation (EBMT) criteria modified to include near complete remission (nCR) and very good partial remission (VGPR","groups":[{"description":"Bendamustine: On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\\^2, and then to 60 mg/m\\^2 bendamustine on days 1 and 4 if ANC is not \\>1 x 10\\^9/L and platelets are not \\>50 x 10\\^9/L on day 1 of each cycle.\n\nPatients will be treated until disease progression after at least one cycle of treatment.\n\nBortezomib: On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\\^2 followed by bendamustine given at 90 mg/m\\^2. Patients will be dose reduced to 75 mg/m\\^2, and then to 60 mg/m\\^2 bendamustine on days 1 and 4 if ANC is not \\>1 x 10\\^9/L and platelets are not \\>50 x 10\\^9/L on day 1 of each cycle.\n\nPatients will be treated until disease progression after at least one cycle of treatment.","id":"OG000","title":"Bortezomib and Bendamustine"}],"populationDescription":"Participant data was not analyzed because PI left institution","reportingStatus":"POSTED","timeFrame":"from initial response to relapse, up to 100 weeks.","title":"Duration of Response of This Regimen.","type":"SECONDARY"}